Minerva Neurosciences NERV
NASDAQ NERV
$3.35 +0.00 (+0.00%)
At close: Sep 30, 2026 · 4:00 PM EDT

Minerva Neurosciences (NERV) Current Deferred Revenue (2016)

Updated

Minerva Neurosciences (NERV) recorded Current Deferred Revenue of $3.53 million in Q3 2016.

Analysis

Minerva Neurosciences (NERV) Current Deferred Revenue (2016) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Minerva Neurosciences 158.21 Mn 158.21 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2016 3.53 Mn
API Access

Minerva Neurosciences Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=NERV&period=max&api_key=YOUR_API_KEY